HSDT Strangle Strategy
HSDT (Solana Company), in the Healthcare sector, (Medical - Devices industry), listed on NASDAQ.
Solana Co. is a medical device firm specializing in neurotechnology, dedicated to improving neurological wellness. The company's strategy involves developing, licensing, and acquiring innovative, non-invasive platform technologies. These technologies are designed to enhance the brain's intrinsic capacity for self-healing and mitigate the effects of neurological diseases or trauma. A prime example of their work is the development of an investigational portable neuromodulation stimulator. This device uniquely delivers neurostimulation through the tongue. Clinical studies have indicated that this approach significantly enhances the efficacy of physical exercises for individuals experiencing neurological symptoms stemming from conditions like disease or trauma, including mild-to-moderate traumatic brain injury.
HSDT (Solana Company) trades in the Healthcare sector, specifically Medical - Devices, with a market capitalization of approximately $101.0M, a beta of 1.03 versus the broader market, a 52-week range of 1.185-25.5, average daily share volume of 400K, a public-listing history dating back to 2014, approximately 21 full-time employees. These structural characteristics shape how HSDT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.03 places HSDT roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on HSDT?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current HSDT snapshot
As of June 29, 2026, spot at $1.73, ATM IV 28.80%, IV rank 5.99%, expected move 8.26%. The strangle on HSDT below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on HSDT specifically: HSDT IV at 28.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a HSDT strangle, with a market-implied 1-standard-deviation move of approximately 8.26% (roughly $0.14 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated HSDT expiries trade a higher absolute premium for lower per-day decay. Position sizing on HSDT should anchor to the underlying notional of $1.73 per share and to the trader's directional view on HSDT stock.
HSDT strangle setup
The HSDT strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With HSDT near $1.73, the first option leg uses a $1.82 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed HSDT chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 HSDT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.82 | N/A |
| Buy 1 | Put | $1.64 | N/A |
HSDT strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
HSDT strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on HSDT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on HSDT
Strangles on HSDT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the HSDT chain.
HSDT thesis for this strangle
The market-implied 1-standard-deviation range for HSDT extends from approximately $1.59 on the downside to $1.87 on the upside. A HSDT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current HSDT IV rank near 5.99% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on HSDT at 28.80%. As a Healthcare name, HSDT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to HSDT-specific events.
HSDT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. HSDT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move HSDT alongside the broader basket even when HSDT-specific fundamentals are unchanged. Always rebuild the position from current HSDT chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on HSDT?
- A strangle on HSDT is the strangle strategy applied to HSDT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With HSDT stock trading near $1.73, the strikes shown on this page are snapped to the nearest listed HSDT chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are HSDT strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the HSDT strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 28.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a HSDT strangle?
- The breakeven for the HSDT strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current HSDT market-implied 1-standard-deviation expected move is approximately 8.26%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on HSDT?
- Strangles on HSDT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the HSDT chain.
- How does current HSDT implied volatility affect this strangle?
- HSDT ATM IV is at 28.80% with IV rank near 5.99%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.